Point mutations regarded as missense mutations cause splicing defects in the factor XI gene.

Area of Science:

• Genetics
• Molecular Biology
• Hematology

Background:

• Point mutations in the factor XI (F11) gene, specifically c.616C>T (P188S), c.1060G>A (G336R), and c.1693G>A (E547K), were previously classified as missense mutations.
• Surprisingly, cellular expression of these mutations resulted in significantly higher F11 antigen levels than observed in patients.

Observation:

• The study investigated whether these exonic mutations could induce splicing defects.
• Analysis of patient mRNA revealed aberrant splicing for c.1693G>A and undetectable mRNA for c.616C>T and c.1060G>A, suggesting degradation.
• Minigene assays confirmed that c.616C>T causes exon 7 skipping and mutations in exons 8-10 decrease normal splicing.

Findings:

• The three F11 mutations are located within predicted exonic splicing enhancers (ESEs).
• Aberrant splicing, including exon skipping and mRNA degradation, was observed.
• In silico analysis and compensatory mutations suggest these ESEs are crucial for proper splicing.

Implications:

• These findings reveal a novel mechanism of mutation in the F11 gene.
• It is crucial to conduct expression studies and mRNA analysis to accurately classify point mutations, distinguishing splicing defects from true missense mutations.
• This research emphasizes the importance of comprehensive mutation analysis in genetic diagnostics.